Scrip Asia 100 - Emerging and trailblazing
This article was originally published in Scrip
The breadth of content in this first edition of the Scrip Asia 100 reflects the diversity of Asia itself. From afar, the region might appear to be a bloc of similar countries and cultures. But anyone even superficially familiar with this part of the world knows that it cannot be viewed as a homogenous whole.
You may also be interested in...
Corporate consolidation and specialization were major threads running through the 2010s in Japan. Reimbursement pricing issues continued to dominate the policy sphere while new forms of therapy benefited from positive regulatory reforms.
BeiGene licenses antibody therapeutics for Castleman’s disease and high-risk neuroblastoma.
BeiGene’s license agreement with Leap Therapeutics covers Asia, except for Japan, along with Australia and New Zealand. Apollomics obtains rights in China and beyond to GlycoMimetics’ e-selectin antagonists.